The limitations of some European healthcare databases for monitoring the effectiveness of pregnancy prevention programmes as risk minimisation measures
- 11 December 2017
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 74 (4) , 513-520
Abstract
Pregnancy prevention programmes (PPPs) exist for some medicines known to be highly teratogenic. It is increasingly recognised that the impact of these risk minimisation measures requires periodic evaluation. This study aimed to assess the extent to which some of the data needed to monitor the effectiveness of PPPs may be present in European healthcare databases.Keywords
Funding Information
- Seventh Framework Programme (260598)
This publication has 36 references indexed in Scilit:
- Occurrence of pregnancy and pregnancy outcomes during isotretinoin therapyCanadian Medical Association Journal, 2016
- Compliance with pregnancy prevention plan recommendations in 8672 French women of childbearing potential exposed to acitretinPharmacoepidemiology and Drug Safety, 2015
- Healthcare databases in Europe for studying medicine use and safety during pregnancyPharmacoepidemiology and Drug Safety, 2014
- A comparison of pregnancy prevention programmes in EuropeExpert Opinion on Drug Safety, 2014
- The Danish National Patient RegisterScandinavian Journal of Public Health, 2011
- Compliance with pregnancy prevention programmes of isotretinoin in Europe: a systematic reviewBritish Journal of Dermatology, 2011
- EUROCAT: 25 years of European surveillance of congenital anomalies: Table 1Archives of Disease in Childhood - Fetal and Neonatal Edition, 2005
- Toxicity of Retinoids in Humans and AnimalsJournal of Toxicology: Toxin Reviews, 1986
- Retinoic Acid EmbryopathyNew England Journal of Medicine, 1985
- THALIDOMIDE AND CONGENITAL ABNORMALITIESThe Lancet, 1961